A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
Cancer Chemother Pharmacol. 2017 Aug;80(2):355-361. doi: 10.1007/s00280-017-3363-0. Epub 2017 Jun 27.
Cancer Chemother Pharmacol. 2017.
PMID: 28656383
Free PMC article.
Clinical Trial.